Chevy Chase Trust Holdings, Inc. Vertex Pharmaceuticals Inc Transaction History

Chevy Chase Trust Holdings, Inc.

$30.3 Billion
Q1 2024

A detailed history of Chevy Chase Trust Holdings, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Chevy Chase Trust Holdings, Inc. holds 443,825 shares of VRTX stock, worth $202 Million. This represents 0.61% of its overall portfolio holdings.

Number of Shares

443,825

Previous 444,949 0.25%

Holding current value

$202 Million

Previous $181 Million 2.47%

% of portfolio

0.61%

Previous 0.65%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	SELL	$407.69 - $446.08 $458,243 - $501,393	-1,124 Reduced 0.25%	443,825 $186 Million
Q4 2023 Jan 24, 2024	BUY	$343.0 - $410.68 $4.91 Million - $5.88 Million	14,311 Added 3.32%	444,949 $181 Million
Q3 2023 Oct 23, 2023	BUY	$338.18 - $362.46 $4.99 Million - $5.34 Million	14,744 Added 3.55%	430,638 $150 Million
Q2 2023 Jul 25, 2023	BUY	$314.42 - $351.91 $24.2 Million - $27.1 Million	77,125 Added 22.77%	415,894 $146 Million
Q1 2023 May 17, 2023	BUY	$283.23 - $323.1 $94.6 Million - $108 Million	334,172 Added 7269.35%	338,769 $107 Million

Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $59.9 Million - $68.3 Million	-211,432 Reduced 97.87%	4,597 $1.45 Billion
Q4 2022 Feb 09, 2023	BUY	$285.76 - $321.48 $17 Million - $19.1 Million	59,356 Added 37.89%	216,029 $62.4 Million
Q3 2022 Nov 04, 2022	BUY	$273.83 - $305.53 $588,460 - $656,583	2,149 Added 1.39%	156,673 $45.4 Million
Q2 2022 Aug 10, 2022	BUY	$234.96 - $292.55 $308,267 - $383,825	1,312 Added 0.86%	154,524 $43.5 Million
Q1 2022 Apr 27, 2022	BUY	$221.42 - $260.97 $102,296 - $120,568	462 Added 0.3%	153,212 $40 Million
Q4 2021 Jan 31, 2022	SELL	$177.01 - $223.45 $1.16 Million - $1.46 Million	-6,536 Reduced 4.1%	152,750 $33.5 Million
Q3 2021 Oct 20, 2021	SELL	$181.39 - $202.99 $1.03 Million - $1.15 Million	-5,666 Reduced 3.43%	159,286 $28.9 Million
Q2 2021 Jul 20, 2021	SELL	$187.49 - $221.1 $1.78 Million - $2.1 Million	-9,520 Reduced 5.46%	164,952 $33.3 Million
Q1 2021 Apr 22, 2021	SELL	$207.02 - $241.31 $2.97 Million - $3.46 Million	-14,332 Reduced 7.59%	174,472 $37.5 Million
Q4 2020 Feb 12, 2021	SELL	$207.01 - $276.09 $3.59 Million - $4.79 Million	-17,366 Reduced 8.42%	188,804 $44.6 Million
Q3 2020 Nov 06, 2020	SELL	$255.65 - $303.1 $3.84 Million - $4.55 Million	-15,023 Reduced 6.79%	206,170 $56.1 Million
Q2 2020 Aug 14, 2020	SELL	$225.48 - $295.8 $1.7 Million - $2.24 Million	-7,558 Reduced 3.3%	221,193 $64.2 Million
Q1 2020 May 13, 2020	BUY	$199.77 - $247.81 $504,619 - $625,968	2,526 Added 1.12%	228,751 $54.4 Million
Q4 2019 Feb 12, 2020	SELL	$166.71 - $223.91 $248,898 - $334,297	-1,493 Reduced 0.66%	226,225 $49.5 Million
Q3 2019 Nov 20, 2019	SELL	$166.23 - $187.09 $77,130 - $86,809	-464 Reduced 0.2%	227,718 $38.6 Million
Q2 2019 Aug 14, 2019	SELL	$164.61 - $190.37 $201,153 - $232,632	-1,222 Reduced 0.53%	228,182 $41.8 Million
Q1 2019 May 13, 2019	BUY	$163.73 - $194.7 $405,395 - $482,077	2,476 Added 1.09%	229,404 $39.1 Million
Q4 2018 Feb 14, 2019	SELL	$151.91 - $192.21 $2.59 Million - $3.27 Million	-17,032 Reduced 6.98%	226,928 $37.6 Million
Q3 2018 Oct 23, 2018	SELL	$167.73 - $192.74 $744,721 - $855,765	-4,440 Reduced 1.79%	243,960 $47 Million
Q2 2018 Aug 02, 2018	BUY	$145.72 - $169.96 $23,169 - $27,023	159 Added 0.06%	248,400 $42.2 Million
Q1 2018 Apr 10, 2018	SELL	$151.6 - $177.13 $723,890 - $845,795	-4,775 Reduced 1.89%	248,241 $40.5 Million
Q4 2017 Jan 22, 2018	SELL	$137.28 - $155.55 $126,572 - $143,417	-922 Reduced 0.36%	253,016 $37.9 Million
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $37.6 Million - $41.2 Million	253,938	253,938 $38.6 Million

Others Institutions Holding VRTX

# of Institutions

1,623

Shares Held

222M

Call Options Held

1.35M

Put Options Held

1.49M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $117B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Chevy Chase Trust Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Chevy Chase Trust Holdings, Inc. with notifications on news.

Account

Chevy Chase Trust Holdings, Inc. Vertex Pharmaceuticals Inc Transaction History